Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)

Yuehong Cui, Tianshu Liu(Sun Yat-sen University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Minzhi Lv(Fudan University), Yian Du(Zhejiang Cancer Hospital), Fenglin Liu(Sun Yat-sen University), Xuefei Wang(Dalian Medical University), Zhenbin Shen(Sun Yat-sen University), Yan Wang(Sun Yat-sen University), Yiyi Yu(Sun Yat-sen University), Song Zheng(Hangzhou First People's Hospital), Yihong Sun(South China Agricultural University)
BMC Cancer
April 4, 2023
10.1186/s12885-023-10773-x
Cited by 14

Related Papers

Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
|The Lancet Oncology|2021|436
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
|癌症：英文版|2023|412